Vivani Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
2.4%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| SLIM-1 Phase 1 Top-line Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, Restricted Cash and Capital Commitments Quarterly28MTarget: Sufficient to fund operations through the first half of 2027
Quarterly Net Loss Quarterly6.8MTarget: Minimize cash burn while advancing clinical programs
Quarterly Research and Development (R&D) Expense Quarterly4.4MTarget: Efficient allocation to SLIM-1 and next-generation NPM-139 development
Watch Items
- SLIM-1 Phase 1 Clinical Trial InitiationTrigger: First patient dosed in Australia (expected mid-2026)Action: Verify trial commencement and monitor patient enrollment progress.
- SLIM-1 Phase 1 Top-line Data ReadoutTrigger: Release of top-line safety, tolerability, and pharmacokinetic results (expected by end of 2026)Action: Analyze pharmacokinetic profile and safety data to confirm NanoPortal platform feasibility for semaglutide.
- Cortigent Subsidiary SeparationTrigger: Execution of spin-off (Form 10) or IPO (Form S-1)Action: Evaluate the impact on Vivani's balance sheet, including potential loan forgiveness or repayment of transition funding.
- Pre-IND Meeting with U.S. FDA and Phase 2 IND FilingTrigger: Filing of IND application for NPM-139 (expected in 2027)Action: Assess regulatory feedback and prepare for the initiation of the Phase 2 dose-ranging study.
Research as of 19 Jun 2026